Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Deborah Layton

Showing results (41-50 of 54) with videos related to

Pageof 6
Sort By:
Drug Safety|March 31, 2022
A Landscape Analysis of Post-Marketing Studies Registered in the EU PAS Register and ClinicalTrials.gov Focusing on Pregnancy Outcomes or Breastfeeding Effects: A Contribution from the ConcePTION ProjectLeonardo Roque Pereira, Carlos E Durán, Deborah Layton, et al.
British Journal of Clinical Pharmacology|November 16, 2011
Influenza H1N1 (swine flu) vaccination: a safety surveillance feasibility study using self-reporting of serious adverse events and pregnancy outcomesIsla S Mackenzie, Thomas M MacDonald, Saad Shakir, et al.
Pharmacoepidemiology and Drug Safety|August 30, 2024
Contemporary Practice and Considerations for Real-World Data Source Identification and Feasibility AssessmentDony Patel, Sonia Guleria, Lina Titievsky, et al.
Frontiers in Drug Safety and Regulation|December 17, 2025
Background incidence rates from electronic healthcare databases for vaccine safety monitoring: review of challenges from the COVID-19 vaccination campaign and proposal for best practicesSonja Gandhi-Banga, Laurence Serradell, Deborah Layton, et al.
Pharmacoepidemiology and Drug Safety|March 27, 2026
Curriculum in Pharmacoepidemiology Training Programs: A Cross-Sectional Study to Assess Educational Needs and Alignment With Core CompetenciesAmie Goodin, Deborah Layton, Ryan Chung, et al.
Drug Safety|October 16, 2012
Reasons for and time to discontinuation of rimonabant therapy: a modified prescription-event monitoring studyMarjolein J C Willemen, Aukje K Mantel-Teeuwisse, Yvonne Buggy, et al.
Pharmaceutical Medicine|June 6, 2026
An Expert Consensus-Based Review of Considerations for Developing a Quality Management System Framework for Studies Utilising Secondary Data for Real-World Evidence GenerationDeborah Layton, Antonella Porta, Dony Patel, et al.
Pharmacoepidemiology and Drug Safety|April 29, 2024
Use of quantitative bias analysis to evaluate single-arm trials with real-world data external controlsChristen Gray, Eleanor Ralphs, Matthew P Fox, et al.
Drug Safety|July 31, 2025
Epidemiology of Thrombotic Thrombocytopenia Syndrome 2011 to 2022: English Sentinel Network Cohort StudiesJosé M Ordóñez-Mena, Debasish Kar, Xuejuan Fan, et al.
Drug Safety|March 28, 2023
Impact of European Union Label Changes for Fluoroquinolone-Containing Medicinal Products for Systemic and Inhalation Use: Post-Referral Prescribing TrendsNelly F Ly, Clare Flach, Thom S Lysen, et al.
Pageof 6

Showing results (41-50 of 54) with videos related to

Sort By:
Pageof 6
Drug Safety|March 31, 2022
A Landscape Analysis of Post-Marketing Studies Registered in the EU PAS Register and ClinicalTrials.gov Focusing on Pregnancy Outcomes or Breastfeeding Effects: A Contribution from the ConcePTION ProjectLeonardo Roque Pereira, Carlos E Durán, Deborah Layton, et al.
British Journal of Clinical Pharmacology|November 16, 2011
Influenza H1N1 (swine flu) vaccination: a safety surveillance feasibility study using self-reporting of serious adverse events and pregnancy outcomesIsla S Mackenzie, Thomas M MacDonald, Saad Shakir, et al.
Pharmacoepidemiology and Drug Safety|August 30, 2024
Contemporary Practice and Considerations for Real-World Data Source Identification and Feasibility AssessmentDony Patel, Sonia Guleria, Lina Titievsky, et al.
Frontiers in Drug Safety and Regulation|December 17, 2025
Background incidence rates from electronic healthcare databases for vaccine safety monitoring: review of challenges from the COVID-19 vaccination campaign and proposal for best practicesSonja Gandhi-Banga, Laurence Serradell, Deborah Layton, et al.
Pharmacoepidemiology and Drug Safety|March 27, 2026
Curriculum in Pharmacoepidemiology Training Programs: A Cross-Sectional Study to Assess Educational Needs and Alignment With Core CompetenciesAmie Goodin, Deborah Layton, Ryan Chung, et al.
Drug Safety|October 16, 2012
Reasons for and time to discontinuation of rimonabant therapy: a modified prescription-event monitoring studyMarjolein J C Willemen, Aukje K Mantel-Teeuwisse, Yvonne Buggy, et al.
Pharmaceutical Medicine|June 6, 2026
An Expert Consensus-Based Review of Considerations for Developing a Quality Management System Framework for Studies Utilising Secondary Data for Real-World Evidence GenerationDeborah Layton, Antonella Porta, Dony Patel, et al.
Pharmacoepidemiology and Drug Safety|April 29, 2024
Use of quantitative bias analysis to evaluate single-arm trials with real-world data external controlsChristen Gray, Eleanor Ralphs, Matthew P Fox, et al.
Drug Safety|July 31, 2025
Epidemiology of Thrombotic Thrombocytopenia Syndrome 2011 to 2022: English Sentinel Network Cohort StudiesJosé M Ordóñez-Mena, Debasish Kar, Xuejuan Fan, et al.
Drug Safety|March 28, 2023
Impact of European Union Label Changes for Fluoroquinolone-Containing Medicinal Products for Systemic and Inhalation Use: Post-Referral Prescribing TrendsNelly F Ly, Clare Flach, Thom S Lysen, et al.
Pageof 6